Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gfeller

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Science Advances|February 27, 2021
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancerAmélie Cachot, Mariia Bilous, Yen-Cheng Liu, et al.
Nature Cancer|September 22, 2023
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancerSara Bobisse, Valentina Bianchi, Janos L Tanyi, et al.
Nature Biotechnology|October 11, 2024
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapyFlorian Huber, Marion Arnaud, Brian J Stevenson, et al.
Molecular Systems Biology|April 4, 2013
SH3 interactome conserves general function over specific formXiaofeng Xin, David Gfeller, Jackie Cheng, et al.
Science Translational Medicine|April 13, 2018
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancerJanos L Tanyi, Sara Bobisse, Eran Ophir, et al.
Blood Advances|November 26, 2019
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AMLBérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, et al.
Nature Communications|June 6, 2023
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumorsJulien Schmidt, Johanna Chiffelle, Marta A S Perez, et al.
Nature Communications|September 21, 2017
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axisSara Trabanelli, Mathieu F Chevalier, Amaia Martinez-Usatorre, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Science Advances|February 27, 2021
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancerAmélie Cachot, Mariia Bilous, Yen-Cheng Liu, et al.
Nature Cancer|September 22, 2023
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancerSara Bobisse, Valentina Bianchi, Janos L Tanyi, et al.
Nature Biotechnology|October 11, 2024
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapyFlorian Huber, Marion Arnaud, Brian J Stevenson, et al.
Molecular Systems Biology|April 4, 2013
SH3 interactome conserves general function over specific formXiaofeng Xin, David Gfeller, Jackie Cheng, et al.
Science Translational Medicine|April 13, 2018
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancerJanos L Tanyi, Sara Bobisse, Eran Ophir, et al.
Blood Advances|November 26, 2019
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AMLBérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, et al.
Nature Communications|June 6, 2023
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumorsJulien Schmidt, Johanna Chiffelle, Marta A S Perez, et al.
Nature Communications|September 21, 2017
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axisSara Trabanelli, Mathieu F Chevalier, Amaia Martinez-Usatorre, et al.
Pageof 9